公司资料
Guardant Health 股价、新闻与催化剂
- 股票代码:
- GH
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
174.75 USD (-2.02%)
收盘价
最后更新: 2026年10月1日
17.3B USD
市值
股价为何变动
截至 2026年10月1日，GH 下跌 2.02%，收于 $174.75。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Precision Oncology Diagnostics Company
Guardant Health develops blood-based and tissue-based tests for cancer screening, treatment selection, and disease monitoring. Its platform analyzes cell-free DNA and other molecular signals, supported by large clinical datasets, machine learning, centralized laboratories, and regulatory-grade test development.
Advanced-Cancer Testing
Guardant360 tests profile tumor-derived alterations from blood to guide targeted therapy selection in advanced cancer. FDA-approved companion-diagnostic versions support specific oncology drugs, while broader laboratory-developed offerings help clinicians identify actionable mutations when tissue is unavailable or insufficient.
Molecular Residual Disease and Recurrence Monitoring
Guardant Reveal is designed to detect residual disease and recurrence risk after curative-intent treatment. The test extends the company's role from treatment selection in advanced cancer into longitudinal monitoring of patients with earlier-stage disease.
Cancer Screening
Shield is a blood-based colorectal cancer screening test intended to increase screening participation among average-risk adults. Its commercial model depends on primary-care adoption, guideline inclusion, laboratory scale, reimbursement, and the ability to reach patients who do not complete stool-based or endoscopic screening.
Biopharma and Data Services
Guardant works with pharmaceutical companies on clinical-trial testing, companion diagnostics, biomarker development, and real-world data. These collaborations use the same genomic platform and datasets that support clinical testing, creating a second revenue stream alongside physician-ordered tests.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。